nach oben

Drugs

Erschienen in:

01.12.2003 | Adis Drug Profile

Azelnidipine

verfasst von: Keri Wellington, Lesley J. Scott

Erschienen in: Drugs | Ausgabe 23/2003

Einloggen, um Zugang zu erhalten

Abstract

▴ Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for L-type calcium channels that has recently been approved in Japan for the treatment of patients with hypertension.
▴ Results from clinical trials showed that, in 95 patients with mild-to-moderate hypertension, long-term treatment with azelnidipine effectively controls blood pressure (BP). The mean reduction from baseline in sitting systolic/diastolic BP after 1 year of treatment was 27.8/16.6mm Hg.
▴ Among 172 patients with uncontrolled hypertension receiving non-calcium channel antagonist antihypertensive agents, the addition of azelnidipine therapy significantly reduced mean BP in a non-comparative, 1-year study (a reduction from 165.7/95.4mm Hg at baseline to 138.2/79.9mm Hg at study end).
▴ The antihypertensive efficacy of azelnidipine in patients with mild-to-moderate hypertension was shown to be similar to that of amlodipine or nitrendipine in randomised, double-blind studies. Azelnidipine and amlodipine controlled 24-hour BP to a similar extent.
▴ Azelnidipine is generally well tolerated; vasodilator adverse events such as as headache and hot facial flushes account for most of the adverse events. Its use is not associated with reflex tachycardia.

Use of tradenames is for product identification purposes only and does not imply endorsement.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [published erratum appears in JAMA 2003 Jul 9; 290 (2): 197]. JAMA 2003 May 21; 289(19): 2560–72PubMedCrossRef

Guidelines Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003 Jun; 21(6): 1011–53CrossRef

Kendall MJ. Better beta blockade and optimal antihypertensive therapy. Br J Cardiol 2000 Jun; 7(6): 323–7

Ramsay LE, Williams B, Johnston GD, et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999 Sep; 13(9): 569–92PubMedCrossRef

Koike H, Kimura T, Kawasaki T, et al. Azelnidipine, a long-acting calcium channel blocker with slow onset and high vascular affinity [online]. Available from URL: http://www.sankyo.co.jp/lab/e_index.html [Accessed 2003 Sep 29]

Sada T, Mizuno M, Miyama C, et al. Pharmacological properties of azelnidipine, a long-acting calcium channel blocker with high-affinity for vascular tissues (pt 1): calcium-channel blocking actions in receptor binding and isolated blood vessel studies [in Japanese]. Jpn Pharmacol Ther 2002; 30(9): 703–9

Oizumi K, Nishino H, Koike H, et al. Antihypertensive effects of CS-905, a novel dihydropyridine Ca⁺⁺ channel blocker. Jpn J Pharmacol 1989 Sep; 51(1): 57–64PubMedCrossRef

Oizumi K, Miyamoto M, Koike H. Antihypertensive effect of CS-905, a novel dihydropyridine calcium blocker, in conscious hypertensive dogs. Jpn J Pharmacol 1990 Jun; 53(2): 264–6PubMedCrossRef

Oizumi K, Nishino H, Miyake S, et al. Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR. Jpn J Pharmacol 1990 Sep; 54(1): 1–6PubMedCrossRef

10.

Fujisawa M, Yorikane R, Koike H. Analysis of the chronotropic effects of azelnidipine in anesthetized dogs: a comparison with amlodipine and nifedipine [in Japanese]. Jpn Pharmacol Ther 2003; 31(7): 553–64

11.

Arita M, Hashizume T, Tanigawa K, et al. A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1999 Feb; 33(2): 186–92PubMedCrossRef

12.

Kobayashi K, Kamimura S, Okada Y, et al. Long-term effects of CS-905 (azelnidipine) on diurnal blood pressure variation and hemodynamics in patients with essential hypertension [in Japanese]. Rinsho Iyaku 2000; 16(3): 269–81

13.

Tochikubo O, Miyajima E, Kawano Y, et al. Effect of azelnidipine, CS-905, on diurnal blood pressure variation and heart rate variability in patients with essential hypertension [in Japanese]. Rinsho Iyaku 1999; 15(3): 435–50

14.

Yoshinaga K, Iimura O, Abe K, et al. Effect of CS-905 (azelnidipine) on diurnal blood pressure variation in patients with essential hypertension: early phase II clinical study [in Japanese]. Rinsho Iyaku 1999; 15(6): 849–68

15.

Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003 Mar; 26(3): 201–8PubMedCrossRef

16.

Saruta T, Yoshinaga K, Iimura O, et al. The efficacy and safety of CS-905 (azelnidipine) in the treatment of essential hypertensives with renal dysfunction and renal parenchymal hypertensives [in Japanese]. Rinsho Iyaku 1999; 15(6): 1005–31

17.

Kanazawa M, Kohzuki M, Yoshida K, et al. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation. Hypertens Res 2002 May; 25(3): 447–53PubMedCrossRef

18.

Yagil Y, Miyamoto M, Frasier L, et al. Effects of CS-905, a novel dihydropyridine calcium channel blocker, on arterial pressure, renal excretory function, and inner medullary blood flow in the rat. Am J Hypertens 1994 Jul; 7 (7 Pt 1): 637–46PubMed

19.

Oizumi K, Nishino H, Miyamoto M, et al. Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR. Jpn J Pharmacol 1989 Dec; 51(4): 501–8PubMedCrossRef

20.

Oizumi K, Miyamoto M, Koike H. Effects of dihydropyridine Ca blockers on the renal function in nephrotic spontaneously hypertensive rat (SHR). Biol Pharm Bull 1994 Mar; 17(3): 407–10PubMedCrossRef

21.

Satoh K, Yamamoto A, Hoshi K, et al. Effects of azelnidipine, a dihydropyridine calcium antagonist, on myocardial stunning in dogs. Jpn J Pharmacol 1998 Apr; 76(4): 369–76PubMedCrossRef

22.

Tomita K, Nonoguchi H, Marumo F. Effect of CS-905 (azelnidipine) on renal function in essential hypertension [in Japanese]. Rinsho Iyaku 1999; 15(3): 451–63

23.

Yamakado M. Clinical study of CS-905 (azelnidipine) on antiarteriosclerotic effect and protective effect of renal function in patients with essential hypertension [in Japanese]. Rinsho Iyaku 2000; 16(3): 355–73

24.

Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-905, a new calcium antagonist — I: a single dose study on healthy volunteers [in Japanese]. Rinsho Iyaku 2000; 16(2): 163–77

25.

Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-905, a new calcium antagionist — III: a multiple dose study on healthy volunteers [in Japanese]. Rinsho Iyaku 2000; 16(2): 191–205

26.

Sankyo Co. Calblock (azelnidipine) prescribing information. Tokyo: Sankyo Co., 2003

27.

Nakashima M, Kawabata K, Sasahara K. Phase I study of CS-905, a new calcium antagonist — II: a single dose study on healthy vounteers: influence of food intake [in Japanese]. Rinsho Iyaku 2000; 16(2): 179–90

28.

Kuwajima I, Ozawa T, Suzuki Y, et al. Pharmacokinetic study of CS-905 (azelnidipine) in elderly patients with essential hypertension [in Japanese]. Rinsho Iyaku 2000; 16(3): 375–87

29.

Oguchi H, Hora K, Yazaki K, et al. Pharmacokinetics of CS-905 (azelnidipine) in patients with renal insufficiency [in Japanese]. Rinsho Iyaku 1999; 15(5): 765–77

30.

Yoshinaga K, Iimura O, Abe K, et al. Efficacy and safety of CS-905 (azelnidipine) in patients with essential hypertension: early phase II clinical study (pre-pilot and pilot I) [in Japanese]. Rinsho Iyaku 1999; 15(6): 869–90

31.

Yoshinaga K, Iimura O, Abe K, et al. Efficacy and safety of CS-905 (azelnidipine) in patients with essential hypertension: early phase II clinical study (pilot II) [in Japanese]. Rinsho Iyaku 1999; 15(6): 891–905

32.

Yoshinaga K, Iimura O, Abe K, et al. Late phase II study of CS-905, azelnidipine, in patients with essential hypertension: a multi-center, double-blind comparative study for evaluation of optimal dose [in Japanese]. Rinsho Iyaku 1999; 15(6): 907–42

33.

Yoshinaga K, Iimura O, Abe K, et al. Efficacy and safety of CS-905 (azelnidipine) monotherapy on essential hypertension in the long-term treatment [in Japanese]. Rinsho Iyaku 1999; 15(6): 943–83

34.

Yoshinaga K, Iimura O, Abe K, et al. A multicenter double-blind comparison study of CS-905 (azelnidipine) with nitrendipine in patients with essential hypertension [in Japanese]. Rinsho Iyaku 2000; 16(5): 671–739

35.

Hirai A, Terano T, Saito Y. Efficacy and safety of CS-905 (azelnidipine) combination therapy on essential hypertension [in Japanese]. Rinsho Iyaku 1999; 15(9): 1505–45

36.

Yoshinaga K, Hirai A, Yamakado M. Evaluation of safety profile of CS-905, azelnidipine, in clinical trials of hypertension [in Japanese]. Rinsho Iyaku 2000; 16(5): 741–62

Titel: Azelnidipine
verfasst von: Keri Wellington
Lesley J. Scott
Publikationsdatum: 01.12.2003
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 23/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200363230-00004

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23/2003

Vardenafil

Azelnidipine

Combined Hepatitis A and B Vaccines

Erratum to: Tadalafil

Azelnidipine

Azelnidipine